Enhanced formation of advanced oxidation protein products in IBD

Inflammatory Bowel Diseases

Volumn 14, Issue 6, 2008, Pages 794-802

  Krzystek Korpacka, Malgorzata ^a   Neubauer, Katarzyna ^a   Berdowska, Izabela ^a   Boehm, Dorota ^a   Zielinski, Bogdan ^a   Petryszyn, Pawel ^a   Terlecki, Grzegorz ^a   Paradowski, Leszek ^a   Gamian, Andrzej ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Advanced oxidation protein products (AOPPs); Crohn's disease; Inflammatory bowel disease (IBD); Oxidative stress; Ulcerative colitis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; C REACTIVE PROTEIN; CATALASE; SUPEROXIDE DISMUTASE; TRANSFERRIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE; TRANSFERRIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; LIPIDS; MALE; MALNUTRITION; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; ROC CURVE; TRANSFERRIN;

EID: 46049091611     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20383     Document Type: Article

References (39)

1. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol. 2005;11:2371-2384.
2. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015-2021.
3. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997-2015.
4. Mera K, Anraku M, Kitamura K, et al. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun. 2005;334: 1322-1328.
5. Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immun. 1998;161:2524-2532.
6. Kalousova M, Zima T, Tesar V, et al. Advanced glycoxidation end products in chronic diseases - clinical chemistry and genetic background. Mutat Res. 2005;579:37-46.
7. Witko-Sarsat V, Gausson V, Nguyen A-T, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003;64:82-91.
8. Peng K, Wu X, Zhao H, et al. Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Chin Med J. 2006;119:1088-1093.
9. Baskol G, Demir H, Baskol M, et al. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct. 2006;24:307-311.
10. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relation with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2007;77:188-192.
11. Tesarova P, Kalousova M, Soukupova J, et al. Carbonyl and oxidative stress in patients with breast cancer - is there a relation to the stage of the disease? Neoplasma. 2007;54:219-224.
12. Kosova F, Cetin B, Akinci M, et al. Advanced oxidation protein products, ferrous oxidation in xylenol orange, malondialdehyde levels in thyroid cancer. Ann Surg Oncol. 2007;14:2616-2620.
13. Wykretowicz A, Adamska K, Krauze T, et al. The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults. Free Radic Res. 2007;41:645-649.
14. Selmeci L, Seres L, Antal M, et al. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med. 2005; 43:294-297.
15. Rentsch M, Beham A, Schlitt HJ, Jauch KW. Crohn's Disease Activity Index and Vienna Classification - is it worthwhile to calculate before surgery? Dig Surg. 2006;23:241-249.
16. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-32.
17. Matteucci E, Biasci E, Giampietro O. Advanced oxidation protein products in plasma: stability during storage and correlation with other clinical characteristics. Acta Diabetol. 2001;38:187-189.
18. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
19. O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenerol. 2006;20:561-573.
20. Rice-Evans CA, Diplock AT, Symons MCR. Techniques in free radical research, Amsterdam, The Netherlands: Elsevier Science Publishers BV; 1991.
21. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Ling KLE, et al. Low-density lipoprotein is the major carrier of lipid hydroperoxides in plasma. Biochem J. 1996;313:781-786.
22. Bartosz G. Druga twarz tlenu. Wolne rodniki w przyrodzie. 2nd ed. Warsaw, Poland: Wydawnictwo Naukowe PWN; 2004.
23. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890.
24. Valli A, Sulimasn ME, Meert N, et al. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta. 2007;379:87-94.
25. McKenzie SJ, Baker MS, Buffinton GD, et al. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest. 1996;98:136-141.
26. Khan WI, Motomura Y, Wang H, et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol. 2006; 291:G803-G811.
27. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51:597-604.
28. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal failure. Circulation. 2002;106:2212-2217.
29. Selmeci L, Szekely M, Soos P, et al. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res. 2006;40:952-958.
30. Gallardo JM, Prado-Uribe M, Amato D, et al. Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res. 2007;38:34-38.
31. Stange EF, Travis SPL, Vermeire S, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55:i1-i15.
32. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
33. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the colesterol efflux capacity of serum using Fu5AH cell system. Metabolism Clin Exp. 2006;55:980-988.
34. Keshavarzian A, Banan A, Farhadi A, et al. Increase in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut. 2003;52:720-728.
35. Travis SPL, Stange EF, Lemann M, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55:i16-i35.
36. Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002;35: 569-572.
37. Glemziene I, Kalibaitiene D, Kalpokaite Z, et al. The role of oxidative stress in digestive tract morbidity. Acta Medica Lituanica. 2001;8:15-18.
38. Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
39. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201:28-36.